Country for PR: United Kingdom
Contributor: PR Newswire Europe
Friday, December 10 2021 - 00:00
AsiaNet
The innovative software "CAAS vFFR" by Pie Medical Imaging for the non-invasive physiological assessment of intermediate coronary lesions is the subject of FAST III, a multicenter European clinical trial which will investigate the effectiveness of the vessel Fractional Flow Reserve (vFFR) guided revascularization as compared to conventional FFR guided revascularization
MAASTRICHT, Netherlands, December 7, 2021 /PRNewswire-AsiaNet/--

Pie Medical Imaging ("PMI"), a global leader in cardiac imaging, part of the 
Esaote Group, today announced the beginning of FASTIII, a multicenter 
randomized clinical trial which will investigate the use of angiography-based 
vessel fractional flow reserve (CAAS vFFR) in patients undergoing coronary 
revascularization procedures. 
 
The FASTIII trial, that is led by Dr. Joost Daemen (cardiologist at the 
Thoraxcenter at the Erasmus University Medical Center, Rotterdam, The 
Netherlands), is an investigator initiated international, multi-center 
randomized, non-inferiority trial aiming to enroll a total of 2228 patients, in 
7 European countries and 35 hospitals and is sponsored by the European 
Cardiovascular Research Institute (ECRI).

The FAST III study aims to demonstrate non-inferiority of CAAS vFFR guided 
revascularization as compared to a conventional invasive wire based FFR guided 
revascularization in patients with either stable coronary syndrome or non-ST 
segment elevation myocardial infarction and intermediate coronary artery 
lesions. 

vFFR can assess whether a coronary artery narrowing is functionally severe and 
requires treatment. CAAS vFFR allows doing so without the need of invasive 
wires- that are part of the routine practice to measure pressure gradients 
(FFR) – and adenosine. 

The high diagnostic accuracy of CAAS vFFR, which calculates pressure drop and 
vFFR value using angiography images only was recently confirmed by the results 
of FAST I, FAST Extend and FASTII studies which validated vFFR as an accurate 
and easy to use tool to assess coronary physiology.

"We are confident that this new study will lead to a broader use of methods 
based on angiographic images for a safe and accurate assessment of severity and 
percentage of artery stenosis" said René Guillaume, PMI Managing Director.
The trial is funded by research grants from Pie Medical Imaging (Maastricht, 
the Netherlands) and Siemens Healthineers GmbH (Erlangen, Germany).

About Pie Medical Imaging

Pie Medical Imaging BV is a world leader in analysis and visualization of 
cardiovascular images in Maastricht (The Netherlands), it hosts the global 
sales for the CAAS and 3mensio product lines. PMI and 3mensio Medical Imaging 
are part of the Esaote Group, leader in the biomedical equipment sector. More 
information about PMI is available at www.piemedicalimaging.com

Photo - 
https://mma.prnewswire.com/media/1704306/CAAS_vFFR_real_time_cathlab.jpg 
Logo - https://mma.prnewswire.com/media/1511581/PMI__Logo.jpg


SOURCE: Pie Medical Imaging





Translations

Japanese